| GLP-1 Agonists May Help People With Diabetes and Long COVID |
| Saturday, July 11, 2026 01:34 PM |
| GLP-1 agonists have become popular treatments for weight loss and type 2 diabetes, and newer studies suggest other health benefits as well. Findings from experiments on mice, published this week in the Journal of Virology, suggest that the drugs may offer benefits to another patient population: people with type 2 diabetes who suffer from pulmonary fibrosis months or years after infection with SARS-CoV-2, the virus that causes COVID-19. Read more. |